Navigation Links
Amgen to Present at the Leerink Swann Global Healthcare Conference
Date:2/14/2012

THOUSAND OAKS, Calif., Feb. 13, 2012 /PRNewswire/ -- Amgen (NASDAQ: AMGN) will present at the Leerink Swann Global Healthcare Conference at 9:30 a.m. Eastern Standard Time  on Thursday, Feb. 16, 2012, at the Waldorf Astoria Hotel in New York City.  Jonathan M. Peacock, executive vice president and chief financial officer at Amgen, will present at the conference. Live audio of the presentation can be accessed from the Events Calendar on Amgen's website, www.amgen.com, under Investors.

About Amgen
Amgen discovers, develops, manufactures and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe, effective medicines from lab to manufacturing plant to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, bone disease and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives. To learn more about our pioneering science and vital medicines, visit www.amgen.com.  Follow us on www.twitter.com/amgen.

CONTACT: Amgen, Thousand Oaks
Christine Regan, 805-447-5476 (media)
Arvind Sood, 805-447-1060 (investors)

(Logo: http://photos.prnewswire.com/prnh/20081015/AMGENLOGO)

 

 

 

 


'/>"/>
SOURCE Amgen
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Amgen to Acquire Micromet
2. Amgen Announces Webcast of 2011 Fourth Quarter and Full Year Financial Results
3. Amgen to Present at the 30th Annual J.P. Morgan Global Healthcare Conference
4. Kevin Sharer, Amgen Chairman and CEO, Announces Plan to Retire With Robert Bradway to Become CEO on May 23, 2012; Sharer Will Continue as Chairman of the Board Until End of 2012
5. Amgen Announces 2012 First Quarter Dividend
6. Amgen Presents Final Results from the Largest Phase 3 Open-Label Study Assessing the Safety and Efficacy of Nplate® (Romiplostim)
7. Amgen and FDA Agree to Modify Nplate® (Romiplostim) Risk Evaluation and Mitigation Strategy
8. Amgen’s Third Quarter 2011 Revenue and Adjusted Earnings Per Share (EPS) Each Increased 3 Percent to $3.9 Billion and $1.40
9. Amgen Appoints Anthony (Tony) Hooper Executive Vice President Global Commercial Operations
10. Amgen Appoints Robert A. Bradway to the Companys Board of Directors
11. Amgen Announces 2011 Fourth Quarter Dividend
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... ... July 31, 2015 , ... Global Resorcinol ... premium industry insights on the global resorcinol industry. The report highlights the various ... vivid market scenarios and analysis of primary and secondary inputs from the existing ...
(Date:7/30/2015)... (PRWEB) , ... July 31, 2015 , ... Ralco is ... Center at the Lyon County Fair to be held August 5-9 in Marshall. The ... where their meals come from and how agriculture impacts their daily lives. This unique ...
(Date:7/30/2015)... ... July 30, 2015 , ... Tronics, ... as Sales & Marketing Director. , With more than 25 years of ... for reinforcing Tronics’ business development activities worldwide. He brings to the company his ...
(Date:7/30/2015)... ... July 30, 2015 , ... Leading regenerative veterinary medicine company, ... canine osteoarthritis stem cell product, currently under development for FDA approval. The product ... marketed in the US by Aratana. This product, termed AT-016, is an allogeneic ...
Breaking Biology Technology:Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 2Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 3Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 4Ralco Announces Primary Sponsorship of Ralco Enrichment Center at Lyon County Fair 2Tronics appoints Francois Vieillard as Sales and Marketing Director 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 3
... AUSTIN, Texas , Feb. 15 Dr. Robert Johnson ... at the 5th Annual Stem Cell Summit in New York ... most recent data proving the efficacy of point of care adult stem ... own cells derived from bone marrow to inhibit bone growth in spinal ...
... the Nano/Bio Interface Center of the University of ... to electrical current in a molecular circuit. The ... respond to electromagnetic waves by creating surface plasmons ... similar to that of photovoltaic solar cells. ...
... ... DNalysis have successfully rolled out PatentSafe, protecting their forensic results and allowing their scientists ... ... 2010 -- Amphora Research Systems is pleased to announce that DNalysis have implemented PatentSafe ...
Cached Biology Technology:SpineSmith to Present at the 5th Annual Stem Cell Summit 2SpineSmith to Present at the 5th Annual Stem Cell Summit 3Penn material scientists turn light into electrical current using a golden nanoscale system 2Independent Forensics Company DNalysis Implement Amphora's PatentSafe Solution to Preserve and Secure Findings 2Independent Forensics Company DNalysis Implement Amphora's PatentSafe Solution to Preserve and Secure Findings 3
(Date:7/13/2015)... , July 13, 2015 Synaptics ... of human interface solutions, today announced sampling of ... and display driver integration (TDDI) product targeting smartphones ... first to combine Synaptics , best-in-class touch ... display driver technology developed in the company,s Japan ...
(Date:7/9/2015)...  Unchained Labs just can,t get enough biologics ... Nano. Avid Nano designs, develops and manufactures highly ... Also today, Unchained Labs UNcaged the pUNk, ... protein sizing system. The pUNk is a high-performance ... size distribution, aggregation population and molecular weight. Its ...
(Date:7/8/2015)... , July 8, 2015  Trovagene, Inc. ... molecular diagnostics, today announced the launch of a ... Company,s Precision Cancer Monitoring℠ (PCM) technology for predicting ... one or a combination of the novel immunotherapy ... (nivolumab), a PD-1 inhibitor. The 50-patient study will ...
Breaking Biology News(10 mins):Synaptics Announces Sampling of Second Generation TDDI Solutions 2Synaptics Announces Sampling of Second Generation TDDI Solutions 3Unchained Labs just can't get enough, acquires Avid Nano, rocks out the new pUNk! 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4
... R.I. [Brown University] In a brief paper in ... a new, freely available Web-based program called Spliceman for ... splicing of messenger RNA, potentially leading to disease. ... mutations and computes how likely these single nucleotide variants ...
... is key to addressing the major challenges facing humanity in ... Frommer. In a Perspective published in The Plant Cell ... technology is key to transforming plant biology in order to ... of energy into the biosphere, provide food and materials used ...
... cardiac pacemakers turns to an unlikely source: vibrations from ... of Michigan designed a device that harvests energy from ... it to electricity to run a pacemaker or an ... the heart to keep it beating in a healthy ...
Cached Biology News:Will a genetic mutation cause trouble? Ask Spliceman 2The future of plant science a technology perspective 2Heart-powered pacemaker could one day eliminate battery-replacement surgery 2
... is primarily used for the preparation of ... for tracing. NH2-Reactive B-Phycoerythrin, a component of ... can easily make a covalent bond with ... without any activation process. Filtration Tube included ...
Mouse polyclonal antibody raised against a partial recombinant RDH5. NCBI Entrez Gene ID = 5959...
Mouse monoclonal antibody raised against a partial recombinant KRT4. NCBI Entrez Gene ID = KRT4...
Mouse monoclonal antibody raised against a partial recombinant ARHGEF11. NCBI Entrez Gene ID = ARHGEF11...
Biology Products: